Geneva University Hospitals

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
목요일, 3월 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer

Retrieved on: 
월요일, 1월 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, RNA, Geneva University Hospitals, University, Messenger, Lawrence Berkeley National Laboratory, Joint Genome Institute, DNA, Therapy, Genomics, World Health Organization, Growth, CSO, Molecular medicine, Synthetic biology

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).
  • “I’m thrilled to assume my new role, and to continue leading Nutcracker’s research team through a new era of growth and innovation,” said Dr. Deutsch.
  • Before joining Nutcracker, Dr. Deutsch was a research scientist at Lawrence Berkeley Lab and led the DNA synthesis foundry at the Joint Genome Institute.
  • “Sam has brought invaluable experience and leadership to Nutcracker since its establishment in 2018,” said Igor Khandros, CEO.

AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE Randomized, Controlled Trial

Retrieved on: 
화요일, 8월 8, 2023
Science, Biotechnology, Research, Surgery, Health, Medical Devices, Health Technology, Clinical Trials, Geneva University Hospitals, Journal of Orthopaedic Trauma, Osteoporosis, Senior, Internal medicine, Hip, Boston Medical Center, Woman, Bone disease, Trial of the century, Bone, Organization, Andrew Kerr (festival co-founder), Local, Patient, Fracture, Risk, Disease, Mortality, Trauma, Dentistry, Medical device

The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria.

Key Points: 
  • The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria.
  • RESTORE is expected to include more than 50 study sites and enroll at least 650 patients.
  • “The initiation of RESTORE and the enrollment of the 150th patient is a major milestone for the Company,” explained James Pilachowski, Senior Vice President of Hip Program.
  • I look forward to reviewing the data generated by RESTORE with other clinicians and organizations committed to addressing secondary hip fracture risk.”

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
금요일, 8월 4, 2023
University of Geneva, Tau, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Luxembourg Centre for Systems Biomedicine, Myawaddy Mingyi U Sa, ABATE, Tax, PET, Financial statement, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, Target, University of Gothenburg, AAIC, MD, Patient, Medicine, Polhemus Memorial Clinic, Diagnosis, Poster, AD, FDA, CHF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, University of Luxembourg, ALS, Food, Conference, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Fine chemical, Vaccine, Amyloid beta

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.
  • The first patient with Parkinson’s disease was dosed in the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune’s wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy.
  • The Company’s cash balance provides sufficient capital resources to progress into at least Q3 2024 without considering receipt of potential future milestone payments.
  • G&A Expenditures: G&A decreased by CHF 0.7 million to CHF 3.7 million, mostly due to a decrease in personnel expenses.

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
금요일, 4월 28, 2023
University of Geneva, Vaccine, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Bank statement, ABATE, Internet, Neurodegenerative disease, Tax, Personalized medicine, LMI, PET, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, TAR, Target, Public expenditure, University of Gothenburg, Investigational New Drug, MJFF, MD, Polhemus Memorial Clinic, CHF, ALS, IND, Diagnosis, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Cryptocurrency

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “Recent accomplishments reaffirm our industry-leading position in developing vaccines and diagnostics for neurodegenerative diseases supporting the transition to targeted treatment and disease prevention.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “Recent accomplishments reaffirm our industry-leading position in developing vaccines and diagnostics for neurodegenerative diseases supporting the transition to targeted treatment and disease prevention.
  • Interim safety and immunogenicity data from ABATE’s AD and DS cohorts are expected in the second half of 2023.
  • PI-2620 is being developed as part of a research collaboration between AC Immune and Life Molecular Imaging.
  • Total cash burn guidance for the full year 2023 remains unchanged ranging from CHF 65 to CHF 75 million.

Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer

Retrieved on: 
월요일, 4월 3, 2023
Mental Health, Technology, Medical Devices, Neurology, Biometrics, Other Health, Biotechnology, Health, Oncology, Artificial Intelligence, Monochorionic twins, Wyss Foundation, Hasso Plattner Institute, Berlin Institute for Advanced Study, Broad Institute, University, Wyss Center for Bio and Neuroengineering, Icahn School of Medicine at Mount Sinai, Bio, Multimedia, Research, Genomics, Mount Sinai, Translation, University of Geneva, Campus Biotech, DSM-IV codes, Digital health, MD, RTÉ Executive Board, Artificial intelligence, Psychiatry, CHF, Stanley Center for Psychiatric Research at Broad Institute, Geneva University Hospitals, Management, Pharmaceutical industry

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.

Key Points: 
  • The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.
  • Erwin Böttinger as its new Chief Executive Officer (CEO).
  • Erwin Böttinger, Chief Executive Officer of the Wyss Center for Bio and Neuroengineering.
  • Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic.

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
수요일, 11월 16, 2022
COVID-19, Infectious Diseases, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.

Key Points: 
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005201/en/

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
수요일, 11월 16, 2022
Health, Infectious Diseases, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).

Key Points: 
  • GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.

clinical data show significantly lower iud procedural pain and bleeding rates with aspivix's novel SUCTION-BASED CERVICAL Device

Retrieved on: 
수요일, 5월 25, 2022
Department, Adolescence, Vacuum, Pain, Company, Michel Bernholc, Traction, Comparison, SA, Birth control, Fear, Norwest Venture Partners, Trauma, HUG, ZKB, European Society of Gynaecological Oncology, New Oakland Child-Adolescent and Family Center, Method, Birth, Advancing Women Artists Foundation, Designated terrorist organisations in Australia, Intrauterine device, Bleeding, IUD, Congress, Safety, Reproduction, Lausanne University Hospital, Geneva University Hospitals, CHUV, Atraumatic Restorative Treatment (ART), Framework Programmes for Research and Technological Development, Reproductive health, PMID, Woman

Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.

Key Points: 
  • Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.
  • During IUD insertion, twice as many nulliparouswomenin the Carevix group were free of pain compared to those in the tenaculum group, and they reported an 88% lower rate of severe pain.
  • Carevixis an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed.
  • A semi-circular, anatomical pad is applied onto the delicate tissue during gynecological procedures, reducing trauma associated with pain and bleeding.

CLINICAL DATA SHOW SIGNIFICANTLY LOWER IUD PROCEDURAL PAIN AND BLEEDING RATES WITH ASPIVIX'S NOVEL SUCTION-BASED CERVICAL DEVICE

Retrieved on: 
수요일, 5월 25, 2022
Department, Adolescence, Vacuum, Pain, Company, Michel Bernholc, Traction, Comparison, SA, Birth control, Fear, Norwest Venture Partners, Trauma, HUG, ZKB, European Society of Gynaecological Oncology, New Oakland Child-Adolescent and Family Center, Method, Birth, Designated terrorist organisations in Australia, Advancing Women Artists Foundation, Intrauterine device, Bleeding, IUD, Congress, Safety, Reproduction, Lausanne University Hospital, Geneva University Hospitals, CHUV, Atraumatic Restorative Treatment (ART), Framework Programmes for Research and Technological Development, Reproductive health, PMID, Woman

Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.

Key Points: 
  • Pain scores were 52% lower with the Carevix device during cervix grasping, 53% lower during cervix stabilization (traction), 30% lower during IUD insertion, and 33% lower during cervix release, compared to tenaculum use.
  • During IUD insertion, twice as many nulliparouswomenin the Carevix group were free of pain compared to those in the tenaculum group, and they reported an 88% lower rate of severe pain.
  • Carevixis an innovative, soft-suction cervical device designed as a modern and gentler alternative to a cervical tenaculum when stabilization of the cervix is needed.
  • A semi-circular, anatomical pad is applied onto the delicate tissue during gynecological procedures, reducing trauma associated with pain and bleeding.